Biodegradable Nanoparticles for Immune Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunosuppressive therapies for autoimmune diseases and organ transplantation are inadequate, leading to chronic rejection and lifelong dependency on medication, with a critical shortage of donor organs and high rejection rates in transplantation.
Innovation Solution
Development of biodegradable nanoparticles with a targeting moiety that selectively binds to T lymphocytes and vascular endothelial cells, loaded with leukemia inhibitory factor (LIF) to promote immune tolerance by guiding T regulatory cells development and reducing immune response aggression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current immunosuppressive therapies are used, then immune response can be suppressed, but chronic rejection and lifelong dependency on medication occur
Solution Approach 1:
The patent uses nanoparticles as intermediary carriers to deliver LIF to specific cell types (T lymphocytes and vascular endothelial cells). The nanoparticles act as a mediator that transports the therapeutic molecule precisely to where it is needed, improving efficacy while reducing systemic side effects and dependency on lifelong immunosuppressive therapy.
Solution Approach 2:
The patent changes the delivery parameter from systemic immunosuppressive therapy to targeted nanoparticle delivery. By altering the delivery mechanism and targeting specific cell populations, the therapy achieves better control of immune response without the harmful chronic effects of conventional lifelong immunosuppression.
2Productivity
If donor organs are increased to meet demand, then transplantation availability improves, but donor organ shortage remains critical
Solution Approach 1:
The patent converts the harmful immune recognition of donor organs as foreign into a beneficial response by using LIF to promote tolerance. This allows better matching between donors and recipients, effectively increasing the usable donor organ pool without requiring more physical donors.
Solution Approach 2:
The patent changes the parameter of tissue compatibility from strict HLA matching to immune tolerance induction. By modifying the immune system's response parameter through LIF treatment, the threshold for acceptable donor-recipient matches is raised, increasing transplant availability.
3Reliability
If aggressive immune responses are allowed, then pathogen clearance improves, but self-tolerance is compromised
Solution Approach 1:
The patent applies local quality by targeting different cell types with different functions: T lymphocytes for immune regulation and vascular endothelial cells for tissue protection. The nanoparticles deliver LIF specifically to these locations, allowing aggressive immune responses against pathogens while maintaining self-tolerance through localized modulation of regulatory cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The targeted delivery of LIF using nanoparticles effectively suppresses aggressive immune responses, reduces chronic vascular rejection, and promotes tolerance to transplanted tissues, potentially reducing the need for lifelong immunosuppression and expanding tissue type matching parameters.
Implementation Method 1
the nanoparticles comprise a targeting moiety that is able to bind selectively to the surface of a T lymphocyte cell and/or of a vascular endothelial cell, wherein the targeting moiety is selected from a monoclonal antibody, a polyclonal antibody, or an antigen-binding antibody fragment
Implementation Method 2
a plurality of biodegradable nanoparticles, wherein the nanoparticles comprise a biodegradable polymer layer
Data Source
Figure 1~2(a)
Figure 2(b)
Figure 3
AI summary
A composition for modulating the immune response in a mammal comprising a pharmaceutically acceptable carrier solution and a plurality of biodegradable nanoparticles, wherein the nanoparticles comprise a targeting moiety that is able to bind selectively to the surface of a T lymphocyte cell and/or of a vascular endothelial cell and wherein the nanoparticles further comprise leukaemia inhibitory factor (LIF). Nanoparticle-mediated targeted delivery of LIF can be used a means to guide tolerogenesis in a patient and has immediate clinical application for recipients of organ grafts and also for patients suffering from autoimmune disease.